Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brain Kinetics of 11C-MK-3168 and JNJ-42165279 Occupancy
NCT02169973Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-42165279 in Social Anxiety Disorder (SAD) and major depressive disorder (MDD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Compartmental Model of the Volume of Distribution of 11C-MK-3168 in Brain at Day 1, Dose Dependent Occupancy of Fatty Acid Amide Hydrolase (FAAH) After Single Dose of JNJ-42165279 up to 5 weeks and 1 more. Started Feb 2014; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
Social Anxiety Disorder (SAD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02169973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169973.